Pyxis Oncology, Inc.

Report azionario NasdaqGS:PYXS

Capitalizzazione di mercato: US$124.2m

Pyxis Oncology Gestione

Criteri Gestione verificati 3/4

Pyxis Oncology Il CEO è Tom Civik, nominato in Feb2026, ha un mandato di meno di un anno. possiede direttamente 0.35% delle azioni della società, per un valore di $ 434.89K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.2 anni e 4.7 anni.

Informazioni chiave

Tom Civik

Amministratore delegato

US$75.9k

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOless than a year
Proprietà del CEO0.4%
Durata media del management1.2yrs
Durata media del Consiglio di amministrazione4.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Sep 12

Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

Summary PYXS is developing micvotabart pelidotin for head and neck squamous cell carcinoma, with key clinical readouts expected in H2'25 and H1'26. While micvotabart pelidotin has shown early efficacy and tolerability, limited patient data and competition raise concerns. PYXS has cash runway into H2'26 but faces risk from potential clinical disappointments, competitor updates, and possible dilutive fundraising. Read the full article on Seeking Alpha
Articolo di analisi • Jun 19

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 07

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Summary Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company’s valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types. Investors should consider PYXS's financial runway, speculative nature, and potential for significant stock appreciation if future trial results are favorable. Despite setbacks, PYXS's valuation appears deeply oversold, presenting a speculative "Buy" opportunity due to its robust pipeline and potential revenue from licensing. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Moment Of Truth Approaches For Pyxis Oncology

Summary Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024. PYXS estimates its current cash will last until H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jun 10

Pyxis Oncology: Promising Research Amid Cash Constraints

Summary Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple solid tumor types, with preliminary data expected in 2024. Pyxis recently announced a workforce reduction and sold the royalties and commercialization rights of Beovu to extend its cash runway. Despite innovative technology, PYXS faces financial constraints and early-stage development risks. A neutral stance on PYXS is prudent due to speculative IP and potential shareholder dilution. Read the full article on Seeking Alpha
Seeking Alpha • Mar 28

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds with a private placement in February 2024 and is cashed into H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Summary Pyxis Oncology is a biotech company focused on developing immunotherapies for cancer treatment. Their most advanced pipeline project is sotigalimab, a CD40 agonist, which has shown promising results in melanoma and liposarcoma. The company has enough funds to continue operating for 5-6 quarters, but future funding may require dilutive financing. Read the full article on Seeking Alpha
Articolo di analisi • Feb 18

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Articolo di analisi • Sep 01

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 15

Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06

Pyxis Oncology press release (NASDAQ:PYXS): Q2 GAAP EPS of -$0.79 beats by $0.06. Pyxis Oncology had cash and cash equivalents of $223 million as of June 30, 2022, and approximately $207 million (preliminary, unaudited) as of August 15, 2022, which is expected to fund operations through the second half of 2024.
Articolo di analisi • Apr 13

We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

AMMINISTRATORE DELEGATO

Tom Civik (56 yo)

less than a year
Mandato
US$75,904
Compensazione

Mr. Thomas Civik, also known as Tom, is Independent Chairman of the Board at ImCheck Therapeutics SAS since March 2023. He is Interim CEO & Director of Pyxis Oncology, Inc. from February 3, 2026. He was In...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Thomas Civik
Interim CEO & Directorless than a yearUS$75.90k0.35%
$ 434.9k
Jitendra Wadhane
Chief Accounting Officer4.8yrsUS$766.75kNessun dato
Balu Balasubramanian
Interim Chief Technology Officer4.3yrsNessun datoNessun dato
Alex Kane
Senior Vice President of Investor Relations & Capital Marketsless than a yearNessun datoNessun dato
Donna Regalado
Head of Human Resources1.3yrsNessun datoNessun dato
Charles Gombar
Senior Vice President of Portfolio & Program Management4.3yrsNessun datoNessun dato
Michael Bui
Senior Vice President of Global Regulatory Affairs1.2yrsNessun datoNessun dato
Supriya Roth
Head of Commercial Development1.2yrsNessun datoNessun dato
Shui He
Head of Biometrics1.2yrsNessun datoNessun dato
Hongwei Wang
Head of ADC Development & Clinical Strategy1.2yrsNessun datoNessun dato
Marsha Crochiere
Head of Translational Medicine & Research1.2yrsNessun datoNessun dato
Chris Cohen
Head of Drug Safety & Pharmacovigilance1.3yrsNessun datoNessun dato
1.2yrs
Durata media

Gestione esperta: Il team dirigenziale di PYXS non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Thomas Civik
Interim CEO & Director4.7yrsUS$75.90k0.35%
$ 434.9k
John Flavin
Independent Chairman7yrsUS$155.90k0.65%
$ 809.5k
Anthony Tolcher
Member of Clinical & Translational Medicine Advisory Board4.9yrsNessun datoNessun dato
Freda Lewis-Hall
Independent Director4.7yrsUS$73.40k0.38%
$ 473.2k
Darren Cline
Independent Director4.7yrsUS$83.40k0.40%
$ 492.8k
Santhosh Palani
Independent Director2.2yrsUS$127.78k0%
$ 0
Jason J. Luke
Member of Clinical & Translational Medicine Advisory Boardno dataNessun datoNessun dato
Christopher O'Donnell
Member of Technical Advisory Board4.1yrsNessun datoNessun dato
Morris Rosenberg
Chairperson of Technical Advisory Boardno dataNessun datoNessun dato
Robert Baffi
Member of Technical Advisory Boardno dataNessun datoNessun dato
Virgil Lawlis
Member of Technical Advisory Boardno dataNessun datoNessun dato
Michael Sun
Member of Technical Advisory Boardno dataNessun datoNessun dato
4.7yrs
Durata media
55.5yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PYXS sono considerati esperti (durata media dell'incarico 4.7 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/24 06:56
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Pyxis Oncology, Inc. è coperta da 13 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Tazeen AhmadBofA Global Research
Bradley CaninoGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.